01530.HK
3SBio Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 16.24
−0.31%Year over year
Reported trailing growth
- Revenue
- +68.2%
- EBITDA
- +175.4%
- EBIT
- +170.3%
- EPS
- +194.5%
- Free cash flow
- +228.9%
- Operating cash flow
- +125.8%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +37.1%
- EBITDA
- +58.7%
- EBIT
- +72.1%
- Net income
- +64.2%
- EPS
- +63.8%
- Free cash flow
- +96.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026